Needham & Company LLC Has Lowered Expectations for Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price

Artiva Biotherapeutics (NASDAQ:ARTV) had its target price lowered by Needham & Company LLC from $23.00 to $18.00 in a research note released on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities analysts have also weighed in on the company. Cantor Fitzgerald decreased their target price on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Tuesday, March 25th. Wedbush reissued an “outperform” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a report on Tuesday, March 25th. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Artiva Biotherapeutics in a report on Wednesday, March 26th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Artiva Biotherapeutics currently has a consensus rating of “Buy” and an average price target of $19.40.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ ARTV opened at $2.13 on Thursday. Artiva Biotherapeutics has a twelve month low of $1.78 and a twelve month high of $17.31. The company has a 50 day moving average of $2.95 and a 200 day moving average of $6.64.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.15). On average, sell-side analysts forecast that Artiva Biotherapeutics will post -4.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. bought a new stake in Artiva Biotherapeutics during the third quarter valued at approximately $166,000. Norges Bank purchased a new position in shares of Artiva Biotherapeutics during the 4th quarter worth $302,000. Barclays PLC bought a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at $304,000. Geode Capital Management LLC increased its stake in shares of Artiva Biotherapeutics by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 315,758 shares of the company’s stock worth $3,184,000 after purchasing an additional 6,828 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in shares of Artiva Biotherapeutics in the 4th quarter worth $52,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.